Cardlytics (NASDAQ:CDLX) has earned a consensus recommendation of “Buy” from the six ratings firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $22.40.

CDLX has been the topic of a number of recent research reports. KeyCorp initiated coverage on Cardlytics in a research note on Tuesday, March 6th. They issued an “overweight” rating and a $23.00 target price on the stock. Wells Fargo initiated coverage on Cardlytics in a research note on Tuesday, March 6th. They issued an “outperform” rating and a $22.00 target price on the stock. Bank of America initiated coverage on Cardlytics in a research note on Tuesday, March 6th. They issued a “neutral” rating and a $19.00 target price on the stock. JPMorgan Chase initiated coverage on Cardlytics in a research note on Tuesday, March 6th. They issued an “overweight” rating and a $23.00 target price on the stock. Finally, SunTrust Banks initiated coverage on Cardlytics in a research note on Tuesday, March 6th. They issued a “buy” rating and a $25.00 target price on the stock.

CDLX stock traded down $0.15 on Wednesday, reaching $13.41. The company had a trading volume of 76,844 shares, compared to its average volume of 93,873. Cardlytics has a 1 year low of $11.10 and a 1 year high of $20.99. The company has a debt-to-equity ratio of -0.27, a quick ratio of 1.77 and a current ratio of 1.77. The firm has a market cap of $271.14 and a P/E ratio of -1.67.

Cardlytics (NASDAQ:CDLX) last posted its earnings results on Monday, March 19th. The company reported ($1.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.35) by $0.25. The company had revenue of $39.27 million during the quarter, compared to analysts’ expectations of $38.48 million. research analysts predict that Cardlytics will post -1.93 earnings per share for the current year.

In other Cardlytics news, CEO Scott D. Grimes purchased 2,600 shares of the business’s stock in a transaction on Tuesday, February 13th. The stock was bought at an average cost of $13.00 per share, for a total transaction of $33,800.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

About Cardlytics

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Analyst Recommendations for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.